Platinum drug sensitivity and resistance in testicular germ cell tumors: two sides of the same coin

References

[1] Einhorn LH.Treatment of testicular cancer: a new and improved model..J Clin Oncol1990;8:1777-81

[2] Singh R,Freemantle SJ.Mechanisms of sensitivity and resistance in testicular germ cell tumors..Cancer Drug Resist2019;2:580-94 PMCID:PMC6752046

[3] Galluzzi L,Michels J,Szabadkai G.Systems biology of cisplatin resistance: past, present and future..Cell Death Dis2014;5:e1257 PMCID:PMC4047912

[4] Cavallo F,Antinozzi C,Houldsworth J.Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition..PLoS One2012;7:e51563 PMCID:PMC3520950

[5] Vaisman A,Umar A,Risinger JI.The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts..Cancer Res1998;58:3579-85

[6] Aebi S,Gordon R,Zheng H.Loss of DNA mismatch repair in acquired resistance to cisplatin..Cancer Res1996;56:3087-90

[7] Drummond JT,Brown R.Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line..J Biol Chem1996;271:19645-48

[8] Fink D,Howell SB.The role of DNA mismatch repair in drug resistance..Clin Cancer Res1998;4:1-6

[9] Brown R,Gallagher WM,Margison GP.hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents..Oncogene1997;15:45-52

[10] Le DT,Smith KN,Bartlett BR.Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade..Science2017;357:409-13 PMCID:PMC5576142

[11] Rodrigues DN,Liu D,Carreira S.Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer..J Clin Invest2018;128:5185 PMCID:PMC6205373

[12] Adra N,Althouse SK,Musapatika D.Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206..Ann Oncol2018;29:209-14

[13] Honecker F,Mayer F,Stoop H.Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors..J Clin Oncol2009;27:2129-36

[14] Bagrodia A,Lee W,Sfakianos JP.Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors..J Clin Oncol2016;34:4000-7 PMCID:PMC5477828

[15] Eid H,Géczi L,Bak M.Mdm-2 expression in human testicular germ-cell tumors and its clinical value..Anticancer Res1999;19:3485-90

[16] Wang S,Aguilar A,Yang CY.Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: progress and challenges..Cold Spring Harb Perspect Med2017;7:a026245 PMCID:PMC5411684

[17] LoRusso PM.Inhibition of the PI3K/AKT/mTOR pathway in solid tumors..J Clin Oncol2016;34:3803-15 PMCID:PMC6366304

[18] Avan A,Giovannetti E.Role of Akt signaling in resistance to DNA-targeted therapy..World J Clin Oncol2016;7:352-69 PMCID:PMC5056327

[19] Albany C,von Herrmann KM,Tam J.Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine..Oncotarget2017;8:2949-59 PMCID:PMC5356854

[20] Jostes S,Fellermeyer M,Hafezi F.The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo..J Cell Mol Med2017;21:1300-14 PMCID:PMC5487916

[21] Steinemann G,Schmidt J,Fähling M.Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer..Mol Oncol2019;13:2679-96 PMCID:PMC6887589

[22] Nappi L,Lum A,Eigl BJ.Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum..J Clin Oncol2019;37:3090-98